dc.contributor.author
Díaz González, Álvaro
dc.contributor.author
Hernández Guerra, Manuel
dc.contributor.author
Pérez Medrano, Indhira
dc.contributor.author
Sapena, Víctor
dc.contributor.author
Riveiro-Barciela, Mar
dc.contributor.author
Barreira Díaz, Ana
dc.contributor.author
Gómez, Elena
dc.contributor.author
Morillas, Rosa M.
dc.contributor.author
Barrio, María del
dc.contributor.author
Escudé, Laia
dc.contributor.author
Mateos, Beatriz
dc.contributor.author
Horta, Diana
dc.contributor.author
Gómez, Judith
dc.contributor.author
Conde, Isabel
dc.contributor.author
Ferre Aracil, Carlos
dc.contributor.author
El Hajra, Ismael
dc.contributor.author
Arencibía, Ana
dc.contributor.author
Zamora, Javier
dc.contributor.author
Fernández, Ainhoa
dc.contributor.author
Salcedo, Magdalena
dc.contributor.author
Molina, Esther
dc.contributor.author
Soria, Anna
dc.contributor.author
Estévez, Pamela
dc.contributor.author
López, Carmen
dc.contributor.author
Álvarez Navascúes, Carmen
dc.date.issued
2023-11-17T12:17:48Z
dc.date.issued
2023-04-01
dc.identifier
https://hdl.handle.net/2445/203780
dc.description.abstract
In patients with non-severe acute or chronic autoimmune hepatitis (AIH) without cirrhosis, clinical practice guidelines recommend indistinct use of prednisone or budesonide. However, budesonide is infrequently used in clinical practice. We aimed to describe its use and compare its efficacy and safety with prednisone as first-line options.
dc.format
application/pdf
dc.publisher
Wolters Kluwer Health
dc.relation
Versió postprint del document publicat a: https://doi.org/10.1097/hep.0000000000000018
dc.relation
Hepatology, 2023, vol. 77, num. 4, p 1095-1105
dc.relation
https://doi.org/10.1097/hep.0000000000000018
dc.rights
(c) American Association for the Study of Liver Diseases, 2023
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
dc.subject
Malalties autoimmunitàries
dc.subject
Autoimmune diseases
dc.title
Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion
